1. Targeted biotherapy for chronic obstructive pulmonary disease
Haodong BAI ; Bingxian SHA ; Ambedkar Kumar YADAV ; Xianghuai XU ; Li YU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):377-382
Chronic obstructive pulmonary disease (COPD) is the most common chronic airway disease. The current status of treatment based mainly on bronchodilators and ICS is not sufficient for all of COPD patients. Various studies have attempted to use biologics targeting specific cytokines and their receptors in COPD patients to alleviate respiratory symptoms or reduce the risk of acute exacerbations. However, they failed to bring significant clinical benefits. More studies are needed to further determine the efficacy of targeted biotherapy for COPD.
2. Use of central neuromodulators in chronic cough
Bingxian SHA ; Haodong BAI ; Wanzhen LI ; Li YU ; Xianghuai XU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):432-439
Chronic cough is a common condition that imposes significant physical, psychological, and social burdens on patients. Although chronic cough is often associated with underlying conditions such as asthma, gastroesophageal reflux disease, and eosinophilic bronchitis, some patients experience uncontrollable coughing that is difficult to attribute to a specific cause. Many of these patients exhibit clinical features of cough hypersensitivity syndrome, providing new directions for research into the treatment of chronic cough. As the pathophysiological mechanisms of chronic cough are further elucidated, treatment approaches for chronic cough are entering a new stage of development. This article summarizes and discusses the mechanisms and clinical evidence of central neuromodulators used in the treatment of chronic cough, suggesting promising clinical applications for these drugs in the future.
3.Targeted biotherapy for chronic obstructive pulmonary disease
Haodong BAI ; Bingxian SHA ; Yadav Kumar AMBEDKAR ; Xianghuai XU ; Li YU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):377-382
Chronic obstructive pulmonary dis-ease(COPD)is the most common chronic airway disease.The current status of treatment based mainly on bronchodilators and ICS is not sufficient for all of COPD patients.Various studies have at-tempted to use biologics targeting specific cyto-kines and their receptors in COPD patients to allevi-ate respiratory symptoms or reduce the risk of acute exacerbations.However,they failed to bring significant clinical benefits.More studies are need-ed to further determine the efficacy of targeted biotherapy for COPD.
4.Use of central neuromodulators in chronic cough
Bingxian SHA ; Haodong BAI ; Wanzhen LI ; Li YU ; Xianghuai XU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):432-439
Chronic cough is a common condition that imposes significant physical,psychological,and social burdens on patients.Although chronic cough is often associated with underlying condi-tions such as asthma,gastroesophageal reflux dis-ease,and eosinophilic bronchitis,some patients ex-perience uncontrollable coughing that is difficult to attribute to a specific cause.Many of these pa-tients exhibit clinical features of cough hypersensi-tivity syndrome,providing new directions for re-search into the treatment of chronic cough.As the pathophysiological mechanisms of chronic cough are further elucidated,treatment approaches for chronic cough are entering a new stage of develop-ment.This article summarizes and discusses the mechanisms and clinical evidence of central neuro-modulators used in the treatment of chronic cough,suggesting promising clinical applications for these drugs in the future.
5.Targeted biotherapy for chronic obstructive pulmonary disease
Haodong BAI ; Bingxian SHA ; Yadav Kumar AMBEDKAR ; Xianghuai XU ; Li YU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):377-382
Chronic obstructive pulmonary dis-ease(COPD)is the most common chronic airway disease.The current status of treatment based mainly on bronchodilators and ICS is not sufficient for all of COPD patients.Various studies have at-tempted to use biologics targeting specific cyto-kines and their receptors in COPD patients to allevi-ate respiratory symptoms or reduce the risk of acute exacerbations.However,they failed to bring significant clinical benefits.More studies are need-ed to further determine the efficacy of targeted biotherapy for COPD.
6.Use of central neuromodulators in chronic cough
Bingxian SHA ; Haodong BAI ; Wanzhen LI ; Li YU ; Xianghuai XU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):432-439
Chronic cough is a common condition that imposes significant physical,psychological,and social burdens on patients.Although chronic cough is often associated with underlying condi-tions such as asthma,gastroesophageal reflux dis-ease,and eosinophilic bronchitis,some patients ex-perience uncontrollable coughing that is difficult to attribute to a specific cause.Many of these pa-tients exhibit clinical features of cough hypersensi-tivity syndrome,providing new directions for re-search into the treatment of chronic cough.As the pathophysiological mechanisms of chronic cough are further elucidated,treatment approaches for chronic cough are entering a new stage of develop-ment.This article summarizes and discusses the mechanisms and clinical evidence of central neuro-modulators used in the treatment of chronic cough,suggesting promising clinical applications for these drugs in the future.
7.Targeted biotherapy for chronic obstructive pulmonary disease
Haodong BAI ; Bingxian SHA ; Yadav Kumar AMBEDKAR ; Xianghuai XU ; Li YU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):377-382
Chronic obstructive pulmonary dis-ease(COPD)is the most common chronic airway disease.The current status of treatment based mainly on bronchodilators and ICS is not sufficient for all of COPD patients.Various studies have at-tempted to use biologics targeting specific cyto-kines and their receptors in COPD patients to allevi-ate respiratory symptoms or reduce the risk of acute exacerbations.However,they failed to bring significant clinical benefits.More studies are need-ed to further determine the efficacy of targeted biotherapy for COPD.
8.Use of central neuromodulators in chronic cough
Bingxian SHA ; Haodong BAI ; Wanzhen LI ; Li YU ; Xianghuai XU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):432-439
Chronic cough is a common condition that imposes significant physical,psychological,and social burdens on patients.Although chronic cough is often associated with underlying condi-tions such as asthma,gastroesophageal reflux dis-ease,and eosinophilic bronchitis,some patients ex-perience uncontrollable coughing that is difficult to attribute to a specific cause.Many of these pa-tients exhibit clinical features of cough hypersensi-tivity syndrome,providing new directions for re-search into the treatment of chronic cough.As the pathophysiological mechanisms of chronic cough are further elucidated,treatment approaches for chronic cough are entering a new stage of develop-ment.This article summarizes and discusses the mechanisms and clinical evidence of central neuro-modulators used in the treatment of chronic cough,suggesting promising clinical applications for these drugs in the future.
9.Targeted biotherapy for chronic obstructive pulmonary disease
Haodong BAI ; Bingxian SHA ; Yadav Kumar AMBEDKAR ; Xianghuai XU ; Li YU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):377-382
Chronic obstructive pulmonary dis-ease(COPD)is the most common chronic airway disease.The current status of treatment based mainly on bronchodilators and ICS is not sufficient for all of COPD patients.Various studies have at-tempted to use biologics targeting specific cyto-kines and their receptors in COPD patients to allevi-ate respiratory symptoms or reduce the risk of acute exacerbations.However,they failed to bring significant clinical benefits.More studies are need-ed to further determine the efficacy of targeted biotherapy for COPD.
10.Use of central neuromodulators in chronic cough
Bingxian SHA ; Haodong BAI ; Wanzhen LI ; Li YU ; Xianghuai XU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):432-439
Chronic cough is a common condition that imposes significant physical,psychological,and social burdens on patients.Although chronic cough is often associated with underlying condi-tions such as asthma,gastroesophageal reflux dis-ease,and eosinophilic bronchitis,some patients ex-perience uncontrollable coughing that is difficult to attribute to a specific cause.Many of these pa-tients exhibit clinical features of cough hypersensi-tivity syndrome,providing new directions for re-search into the treatment of chronic cough.As the pathophysiological mechanisms of chronic cough are further elucidated,treatment approaches for chronic cough are entering a new stage of develop-ment.This article summarizes and discusses the mechanisms and clinical evidence of central neuro-modulators used in the treatment of chronic cough,suggesting promising clinical applications for these drugs in the future.

Result Analysis
Print
Save
E-mail